Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of eighty three dolars, which is more or less 9.11 % above the existing share price of $76.07.
Cherny expects CVS Health Corp to publish earnings per share (EPS) of $0.93 for the earliest quarter of 2021.
The analysts priced targets range from a high of $101 to a low of sixty one dolars.
From the latest earnings report of its, released on 09/30/2020, the company reported a quarterly revenue of $67.06 billion and a net gain of $3.25 billion. The company’s market cap is actually $99.57 billion.
Based on TipRanks.com, Merrill Lynch analyst Michael Cherny is currently ranked with four stars on a 0-5 stars ranking scale, with an average return of 11.5 % along with a 60.53 % success rate.
CVS Health Corp. engages in the provision of health care services. It works through the following segments: Pharmacy Services, Long or retail Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment offers pharmacy benefit management strategies. The retail or Long Term Care segment includes offering of prescribed drugs as well as assortment of general merchandise.
The Health Care Benefits segment offers quite traditional, voluntary and consumer-directed health insurance products as well as associated services, which includes medical, pharmacy, dental, behavioural health, medical management capabilities. The Corporate segment involves in offering management as well as administrative services. The company was developed by Stanley P. Goldstein and Ralph Hoagland in 1963 and it is headquartered in Woonsocket, RI.